Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
Data Science Tools for Successful Technology TransferSpeakers: Thomas Zahel & Christoph Herwig
11 December 2019
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Speaker
Christoph Herwig, PhDProfessorVienna University of Technology
Christoph Herwig, a bioprocess engineer from RWTH Aachen, worked in industry in the design and commissioning of large chemical facilities prior to enter his interdisciplinary PhD studies at EPFL, Switzerland in bioprocess identification. Subsequently he positioned himself at the interface between bioprocess development and facility design in biopharmaceutical industry.
Since 2008, he is full professor for biochemical engineering at the Vienna University of Technology. The research area focuses on the development of data science methods for integrated and efficient bioprocess development along PAT and QbD principles for biopharmaceuticals. In 2013 he founded the company Exputec addressing data science solutions for the biopharma life cycle.
2©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Speaker
Thomas Zahel, PhDHead of InnovationExputec GmbH
Thomas Zahel is head of innovation at Exputec, with outstanding experience in statistics, algorithm development and turning complex challenges into easy concepts for our clients. His background is in bioprocess engineering and he holds a PhD in applied statistics for process development and validation. He is most passionate about developing new statistical methods that turn data into knowledge. He has successfully helped top-ranked biopharmaceutical companies to develop, improve and validate their processes according to regulatory compliance.
3©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
BackgroundRegulatory Context of Technology Transfer
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org6
Product Lifecycle
Process Development
Process Validation• Stage 1: Control Strategy• Stage 2: PPQ• Stage 3: CPV
Commercial Production
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org7
Product Lifecycle
“…establish scientific evidence that a process is capable of consistently delivering quality product.“
FDA, 2011
Process Development
Process Validation• Stage 1: Control Strategy• Stage 2: PPQ• Stage 3: CPV
Commercial Production
QRMPQS, ICH guideline Q10
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org8
Product Lifecycle
Process Development
Process Validation• Stage 1: Control Strategy• Stage 2: PPQ• Stage 3: CPV
Commercial Production
Tech Transfer
Tech Transfer
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org9
Product Lifecycle
Process Development
Process Validation• Stage 1: Control Strategy• Stage 2: PPQ• Stage 3: CPV
Commercial Production
Tech Transfer
Tech Transfer
“The goal of technology transfer activities is to transfer product and process knowledge between development and manufacturing, and within or between manufacturing sites to achieve product realisation. This knowledge forms the basis for the manufacturing process, control strategy, process validation approach and ongoing continual improvement” ICHQ8
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Present Data Science Toolswhich can be applied to the different tasks along
technology transfer activities
Presentation Goal
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
From Data to KnowledgeA data science route to platform based technology transfer
using
process mechanistic and platform knowledge
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Data • Data
Management• Data
Contextualization• Data Integrity
Analysis
Information• Feature
extraction• Scale
independent measures
• Soft-sensors
Knowledge• Statistical
comparability analysis
• Mitigation of differences
PV/CPV
Success Criteria of Technology Transfer
12©2
019 IS
PE – A
LL RIG
HTS R
ESER
VED
Connecting Pharmaceutical Knowledge ISPE.org
Data Fusion & Data Integrity
… features from images
… data from PAT equipment… data from Sensors
Process Development & Production
… data from quality
13©2
019 IS
PE – A
LL RIG
HTS R
ESER
VED
Connecting Pharmaceutical Knowledge ISPE.org
We Need Structured Data: As-IsÄK-01 Äkta
Explorer
ÄK-02 Äkta Pilot chromatography
skid
ÄK-03 Äkta Explorer 100 Amersham
LC-01 Liquid Chromatography System Äkta pure
150 L
LC-02 Liquid Chromatography System Äkta pure
150 M
LC-03 Liquid Chromatography
System Äkta avant 150
Projektzip
Automated Backup
Äkta Chromatography -
Devices
Backup, zum Packen
ausgelagert
Unicorn Report
Run - Formblatt
Multiple spreadsheets
Projekt
QCEmail, Powerpoint, Word, Analyseauftrag
ÄK-05 Äkta Process
Scan
Report
CF-03 Crossflow System Äkta Flux
S
USB
Run - Formblatt
UFDF-Sheet („Template“)Raw Data
Projekt
TF-01 AllegroTM Single Use TFF /
PALL
PALL Analytical Tool
USBProjekt
.chart, .sqliteDerzeit nicht ausgewertet
Auswertung am Computer
Report
Chromatography
Column Packing
UFDF
NF
Run - Formblatt
Projekt
Buffer Prep
Run - Formblatt
Projekt
Scan
HarvestProjekt
14©2
019 IS
PE – A
LL RIG
HTS R
ESER
VED
Connecting Pharmaceutical Knowledge ISPE.org
We Need Structured Data: To-Be
DB+ Analytics
15©2
019 IS
PE – A
LL RIG
HTS R
ESER
VED
Connecting Pharmaceutical Knowledge ISPE.org
From Data to Scale Independent Information
0 5 10 15 20 25 30-0.02
-0.01
0
0.01
0.02
0.03
0.04
0.05
0.06
ProcessTime (days)
grow
th ra
te (1
/hou
rs)
0 5 10 15 20 25 30-0.5
0
0.5
1
1.5
2
2.5
3x 10
7
ProcessTime (days)to
tal c
ell c
onc
(cel
ls/m
l)
16©2
019 IS
PE – A
LL RIG
HTS R
ESER
VED
Connecting Pharmaceutical Knowledge ISPE.org
54321
Make Information Ready forStatistical Analysis: Feature Extraction
4 52.5 2.51 0.5
t
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚()
17©2
019 IS
PE – A
LL RIG
HTS R
ESER
VED
Connecting Pharmaceutical Knowledge ISPE.org
Make Information Ready forStatistical Analysis: Unfolding
Mercier, Sarah M., Bas Diepenbroek, Marcella C.F. Dalm, Rene H. Wijffels, and Mathieu Streefland. “Multivariate Data Analysis as a PAT Tool for Early Bioprocess Development Data.” Journal of Biotechnology, 2013. doi:10.1016/j.jbiotec.2013.07.006.
Features = Information!
Featuresmean, median, max, min, derivative
Yields , qs!
unfolding
MVIAMVDA
18©2
019 IS
PE – A
LL RIG
HTS R
ESER
VED
Connecting Pharmaceutical Knowledge ISPE.org
POLL #1How do you contextualize your different data sources for doing tech transfer data analysis?
19
Manual alignment via Excel
Historian data from Scada/DCS and compare process data trajectories only
Automated process phase detection in time series and alignment of features with ELN, MES, and LIMS data
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Multivariate Data Integrity Analysis (1)
20©2
019 IS
PE – A
LL RIG
HTS R
ESER
VED
Connecting Pharmaceutical Knowledge ISPE.org
Multivariate Data Integrity Analysis (2)
21©2
019 IS
PE – A
LL RIG
HTS R
ESER
VED
Comparability AssessmentThe potential and practical limitations of the working horse equivalence testing
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 23
Comparability Assessment
Scales Sites
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 24
What do we want to verify?
CQ
A
pCPPtarget
Site BSite A
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Comparability Analysis
25
A
C D
B
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Comparability Analysis
26CQ
A
pCPP
CQA
pCPPtarget
target
CQA
pCPPCQ
A
pCPPtarget
target
Site B
Site AOff-setNo off-set
Equal effect
Different effect
A
C D
B
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Comparability Analysis
27CQ
A
pCPP
CQA
pCPPtarget
target
CQA
pCPPCQ
A
pCPPtarget
target
Off-setNo off-set
Equal effect
Different effect
A
C D
BSite B
Site A
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 28
Possible outcomes of comparability study for SDM
Equivalence Test
All responses equivalent Some responses are not equivalent
Mitigate risk of detecteddifferences (e.g. adapt
control strategy)A is more likely than C
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 29
Visual Comparison
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Statistical Comparability Analysis General Workflow
30
2. Define general aim(non-inferiority, equivalence)
1. Define responses for comparison (e.g. CQAs)
3. Define measure of similarity(e.g. difference in means, ratio of variances, multivariate measure)
4. Set EAC for each measure of similarity
5. Calculate required sample size
6. Perform study and conduct Statistical test on equivalence
(e.g. TOST, F test)
“Reflection paper on statistical methodology for the 5 comparative assessment of quality attributes in drug substance development”, EMA 2017“Comparability Protocols for Human Drugs and Biologics: Chemistry, Manufacturing, and Controls Information Guidance for Industry”, FDA 2017
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Statistical Comparability Analysis General Workflow
31
2. Define general aim(non-inferiority, equivalence)
1. Define responses for comparison (e.g. CQAs)
3. Define measure of similarity(e.g. difference in means, ratio of variances, multivariate measure)
4. Set EAC for each measure of similarity
5. Calculate required sample size
6. Perform study and conduct Statistical test on equivalence
(e.g. TOST, F test)
Use KPIs and CQAs
Equivalence
Set Equivalence Acceptance Criteria for eachparameter difference to be accepted
Determine sample size for LS and SDM runs
Perform equivalence test (i.e. TOST) foreach CQA and state practical equivalence
Difference in means, (ratio of variances, multivariate approaches might apply)
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
TOST: Golden Standard for Equivalence Testing
32
Is 95 % of my data (difference of means) within a predefined equivalence margin?
TOST test:1. Define equivalence
boundaries 𝜃𝜃 = EAC2. Calculate a
confidence interval for difference in means
3. Check if interval is completely within upper and lower boundary.
CI = �𝑦𝑦 ± 𝑡𝑡 1−𝛂𝛂,𝑑𝑑𝑑𝑑𝑠𝑠𝑛𝑛
�𝑦𝑦 .. Difference in meanst .. Students T distribution𝛼𝛼 .. Desired alpha error of the test (1-confidence)𝑠𝑠 .. Standard deviation of difference of meansn .. Sample size
1 − 𝛼𝛼 makes CI broader
n makes CI more narrow
𝑦𝑦1 + 𝑦𝑦2 ± 𝑡𝑡 1−𝛼𝛼,𝑑𝑑𝑑𝑑𝑠𝑠1²𝑚𝑚1
+𝑠𝑠2²𝑚𝑚2©2
019 IS
PE – A
LL RIG
HTS R
ESER
VED
Connecting Pharmaceutical Knowledge ISPE.org 33
Equivalence Test Result
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 34
Possible outcomes of comparability study for SDM
Equivalence Test
All responses equivalent Some responses are not equivalent
Mitigate risk of detecteddifferences (e.g. adapt
control strategy)A is more likely than C
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
POLL #2For comparability tests between scales and sites I use?
35
Visual comparison
Golden batch comparison of process data trajectories using fixed standard deviations
Endpoints of quality data from LIMS
Univariate TOST approaches
Multivariate analysis, e.g. Hotelling’s T² test or PCA
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Mitigate Differences in Technology Transfer using Integrated Process ModelsA holistic approach to control strategy
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 37
Data Sources
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 38
Data Sources
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 39
Data Sources
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 40
Data Sources
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 41
Digital Twin
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 42
What Does it Do?
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 43
How Does it Work?
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 44
How Does it Work?
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 45
What Does it Look Like?
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org 46
Holistic Risk Assessment
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
47
How to Set a Control Strategy using an IPM?
UO 1 UO 2 UO 3 UO 4 UO 5 UO 6 UO 7 DS
3.2 4
DSDS
CQA
Elution pH
Load Density
14 24
Upper PAR
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
POLL #3For testing success tech transfer and valid control strategies of the full process chain, I use:
48
Comparison of single unit operations only
Multitude of linkage studies to demonstrate elasticity of the process along perturbations onside of the control strategy
Integrated modelling approach to focus on holistically critical process parameters and limit the number of experiments
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
• From mess to structure• Sound implementation of data management tools is key to data analytics• Tools exist that leverage all possible kind of data (timeseries, pictures, scalar values, …)
• From data to information• Feature extraction based on process understanding enables robust multivariate
information analysis• From information to knowledge
• Statistical comparability analysis forms risk awareness about similarities and differences• Integrated process modelling is essential to derive a control strategy based on holistic
process performance
Conclusions:Successful tech transfer using data science tools
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Q&A
©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
Connecting Pharmaceutical Knowledge ISPE.org
Q&A
51
Contact Information
Christoph Herwig, PhDProfessor, Vienna University of [email protected]
Thomas Zahel, PhDHead of Innovation, Exputec [email protected]
Upcoming Webinars• 23 January - One Size Does Not Fit All:
Strategies for Bringing Advanced Therapy Medicinal Products to Market
Topic Ideas or Feedback? Send to [email protected]
51©2019
ISPE
– ALL
RIGHT
S RES
ERVE
D
mailto:[email protected]:[email protected]
Data Science Tools for Successful Technology TransferSpeaker��Christoph Herwig, PhD�Professor�Vienna University of TechnologySpeaker��Thomas Zahel, PhD�Head of Innovation�Exputec GmbHSlide Number 4BackgroundProduct LifecycleProduct LifecycleProduct LifecycleProduct LifecyclePresentation GoalFrom Data to KnowledgeSuccess Criteria of Technology TransferData Fusion & Data IntegrityWe Need Structured Data: As-IsWe Need Structured Data: To-BeFrom Data to Scale Independent InformationMake Information Ready for�Statistical Analysis: Feature ExtractionMake Information Ready for�Statistical Analysis: UnfoldingPOLL #1Multivariate Data Integrity Analysis (1)Multivariate Data Integrity Analysis (2)Comparability AssessmentComparability AssessmentWhat do we want to verify?Comparability AnalysisComparability AnalysisComparability AnalysisPossible outcomes of comparability study for SDMVisual ComparisonStatistical Comparability Analysis General WorkflowStatistical Comparability Analysis General WorkflowTOST: Golden Standard for Equivalence TestingEquivalence Test ResultPossible outcomes of comparability study for SDMPOLL #2Mitigate Differences in Technology Transfer using Integrated Process ModelsData SourcesData SourcesData SourcesData SourcesDigital TwinWhat Does it Do?How Does it Work?How Does it Work?What Does it Look Like?Holistic Risk AssessmentHow to Set a Control Strategy using an IPM?POLL #3Conclusions:�Successful tech transfer using data science toolsQ&A Q&A